Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | XBP1 | P17861 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | PLAU | P00749 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | RXRA | P19793 | 1/20 | 0.37 |
| ▸ | RXRB | P28702 | 1/20 | 0.37 |
| ▸ | RXRG | P48443 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20101954 | 0.85 | SMN1; SMN2 (0.50) | SMN1; SMN2NPC1GAAMAPTKMT2A | |
| SCHEMBL22997083 | 0.83 | LMNA (0.46) | SMN1; SMN2NPC1TDP1GAAKMT2A | |
| SCHEMBL21048180 | 0.82 | HPGD (0.51) | SMN1; SMN2NPC1GAARAB9AKMT2A | |
| SCHEMBL22049534 | 0.81 | HTT (0.50) | SMN1; SMN2NPC1GAAKMT2AALDH1A1 | |
| SCHEMBL21286879 | 0.80 | HTT (0.49) | SMN1; SMN2NPC1GAAKMT2AALDH1A1 | |
| SCHEMBL20101966 | 0.79 | SMN1; SMN2 (0.38) | SMN1; SMN2NPC1TDP1GAAMAPT | |
| SCHEMBL20108916 | 0.77 | SMN1; SMN2 (0.37) | SMN1; SMN2NPC1TDP1GAAMAPT | |
| SCHEMBL10188491 | 0.76 | SMN1; SMN2 (0.48) | SMN1; SMN2NPC1GAAKMT2AALDH1A1 | |
| SCHEMBL15143207 | 0.76 | SMN1; SMN2 (0.42) | SMN1; SMN2NPC1GAAKMT2AALDH1A1 | |
| SCHEMBL20924657 | 0.75 | SMN1; SMN2 (0.47) | SMN1; SMN2NPC1GAARAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3391888-B1 | MEDICINE FOR TREATING INFLUENZA CHARACTERIZED BY COMPRISING COMBINATION OF CAP-DEPENDENT ENDONUCLEASE INHIBITOR WITH ANTI-INFLUENZA DRUG | SHIONOGI & CO (JP) | 2023-09-27 | — | — | EP | disclosed |
| US-20230287004-A1 | SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUGS THEREOF | SHIONOGI & CO., LTD. (JP) | 2023-09-14 | — | — | US | disclosed |
| US-20230287004-A1 | SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUGS THEREOF | SHIONOGI & CO., LTD. (JP) | 2023-09-14 | — | — | US | disclosed |
| EP-4219508-A1 | SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVE AND PRODRUG THEREOF | Shionogi & Co., Ltd (JP) | 2023-08-02 | — | — | EP | disclosed |
| US-20230040262-A1 | STEREOSELECTIVE PROCESS FOR PREPARING SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2023-02-09 | — | — | US | disclosed |
| US-11040048-B2 | Medicament for treating influenza characterized by combining a Cap-dependent endonuclease inhibitor and an anti-influenza drug | SHIONOGI & CO., LTD. (JP) | 2021-06-22 | — | — | US | disclosed |
| US-20200361958-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUG THEREOF | SHIONOGI & CO., LTD. (JP) | 2020-11-19 | — | — | US | disclosed |
| US-20200283455-A1 | SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUGS THEREOF | SHIONOGI & CO., LTD. (JP) | 2020-09-10 | — | — | US | disclosed |
| US-10759814-B2 | Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof | SHIONOGI & CO., LTD. (JP) | 2020-09-01 | — | — | US | disclosed |
| US-20200261481-A1 | A MEDICAMENT FOR TREATING INFLUENZA CHARACTERIZED BY COMBINING A CAP-DEPENDENT ENDONUCLEASE INHIBITOR AND AN ANTI-INFLUENZA DRUG | SHIONOGI & CO., LTD. (JP) | 2020-08-20 | — | — | US | disclosed |
| EP-3693373-A1 | METHOD FOR STEREOSELECTIVELY PRODUCING SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVE | Shionogi&Co., Ltd. (JP) | 2020-08-12 | — | — | EP | disclosed |
| US-20200247818-A1 | STEREOSELECTIVE PROCESS FOR PREPARING SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2020-08-06 | — | — | US | disclosed |
| US-10633397-B2 | Substituted polycyclic pyridone derivatives and prodrugs thereof | SHIONOGI & CO., LTD. (JP) | 2020-04-28 | — | — | US | disclosed |
| US-10392406-B2 | Substituted polycyclic pyridone derivatives and prodrugs thereof | SHIONOGI & CO., LTD. (JP) | 2019-08-27 | — | — | US | disclosed |
| US-20190169206-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUG THEREOF | SHIONOGI & CO., LTD. (JP) | 2019-06-06 | — | — | US | disclosed |
| US-10294241-B2 | — | — | 2019-05-21 | — | — | US | disclosed |
| US-20190112315-A1 | SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUGS THEREOF | SHIONOGI & CO., LTD. (JP) | 2019-04-18 | — | — | US | disclosed |
| US-20180118760-A1 | SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUGS THEREOF | SHIONOGI & CO., LTD. (JP) | 2018-05-03 | — | — | US | disclosed |
| US-20180118760-A1 | SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUGS THEREOF | SHIONOGI & CO., LTD. (JP) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361958-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUG THEREOF | TYMP, PNP, CYP3A4 | SMN1; SMN2 1950/4885NPC1 1738/4885TDP1 937/4885 |
| US-20200247818-A1 | STEREOSELECTIVE PROCESS FOR PREPARING SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES | RNGTT, CPSF6, ENDOD1 | SMN1; SMN2 2630/4885NPC1 4444/4885TDP1 184/4885 |
| US-20230040262-A1 | STEREOSELECTIVE PROCESS FOR PREPARING SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES | RNGTT, CPSF6, RNASEL | SMN1; SMN2 2614/4885NPC1 4459/4885TDP1 189/4885 |
| US-20230287004-A1 | SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUGS THEREOF | C3AR1, NR4A1, HAVCR2 | SMN1; SMN2 3547/4885NPC1 3542/4885TDP1 2236/4885 |
| US-20190169206-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUG THEREOF | TYMP, PNP, CYP3A4 | SMN1; SMN2 1950/4885NPC1 1738/4885TDP1 937/4885 |
| US-10294241-B2 | — | C3AR1, HAVCR2, NR4A1 | SMN1; SMN2 3158/4885NPC1 2041/4885TDP1 3180/4885 |
| US-10633397-B2 | Substituted polycyclic pyridone derivatives and prodrugs thereof | C3AR1, NR4A1, HAVCR2 | SMN1; SMN2 3547/4885NPC1 3542/4885TDP1 2236/4885 |
| US-10392406-B2 | Substituted polycyclic pyridone derivatives and prodrugs thereof | C3AR1, NR4A1, HAVCR2 | SMN1; SMN2 3547/4885NPC1 3542/4885TDP1 2236/4885 |
| US-20190112315-A1 | SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUGS THEREOF | C3AR1, NR4A1, HAVCR2 | SMN1; SMN2 3547/4885NPC1 3542/4885TDP1 2236/4885 |
| US-20200283455-A1 | SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUGS THEREOF | C3AR1, NR4A1, HAVCR2 | SMN1; SMN2 3547/4885NPC1 3542/4885TDP1 2236/4885 |
| US-10759814-B2 | Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof | TYMP, PNP, CYP3A4 | SMN1; SMN2 1950/4885NPC1 1738/4885TDP1 937/4885 |
| US-20200261481-A1 | A MEDICAMENT FOR TREATING INFLUENZA CHARACTERIZED BY COMBINING A CAP-DEPENDENT ENDONUCLEASE INHIBITOR AND AN ANTI-INFLUENZA DRUG | RNASEH1, RNASEL, RNPEP | SMN1; SMN2 4589/4885NPC1 2543/4885TDP1 492/4885 |
| US-20180118760-A1 | SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUGS THEREOF | C3AR1, NR4A1, HAVCR2 | SMN1; SMN2 3547/4885NPC1 3542/4885TDP1 2236/4885 |
| US-11040048-B2 | Medicament for treating influenza characterized by combining a Cap-dependent endonuclease inhibitor and an anti-influenza drug | RNASEH1, RNPEP, RNASEL | SMN1; SMN2 4672/4885NPC1 2423/4885TDP1 613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.